Multiple sclerosis patients and COVID-19

Coronavirus disease 2019 (COVID-19) is now a major issue for all fields of medicine. Due to the higher mortality rate among patients with chronic diseases, it has also caused concern in patients with multiple sclerosis (MS), who in addition are often receiving immunosuppressive drugs. The aim of thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mado, Hubert, Adamczyk-Sowa, Monika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985914/
https://www.ncbi.nlm.nih.gov/pubmed/33776407
http://dx.doi.org/10.1186/s41983-021-00287-3
_version_ 1783668340910194688
author Mado, Hubert
Adamczyk-Sowa, Monika
author_facet Mado, Hubert
Adamczyk-Sowa, Monika
author_sort Mado, Hubert
collection PubMed
description Coronavirus disease 2019 (COVID-19) is now a major issue for all fields of medicine. Due to the higher mortality rate among patients with chronic diseases, it has also caused concern in patients with multiple sclerosis (MS), who in addition are often receiving immunosuppressive drugs. The aim of this article is to discuss what is currently known about the severity of COVID-19 in MS patients.
format Online
Article
Text
id pubmed-7985914
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-79859142021-03-23 Multiple sclerosis patients and COVID-19 Mado, Hubert Adamczyk-Sowa, Monika Egypt J Neurol Psychiatr Neurosurg Letter to the Editor Coronavirus disease 2019 (COVID-19) is now a major issue for all fields of medicine. Due to the higher mortality rate among patients with chronic diseases, it has also caused concern in patients with multiple sclerosis (MS), who in addition are often receiving immunosuppressive drugs. The aim of this article is to discuss what is currently known about the severity of COVID-19 in MS patients. Springer Berlin Heidelberg 2021-03-23 2021 /pmc/articles/PMC7985914/ /pubmed/33776407 http://dx.doi.org/10.1186/s41983-021-00287-3 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Letter to the Editor
Mado, Hubert
Adamczyk-Sowa, Monika
Multiple sclerosis patients and COVID-19
title Multiple sclerosis patients and COVID-19
title_full Multiple sclerosis patients and COVID-19
title_fullStr Multiple sclerosis patients and COVID-19
title_full_unstemmed Multiple sclerosis patients and COVID-19
title_short Multiple sclerosis patients and COVID-19
title_sort multiple sclerosis patients and covid-19
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985914/
https://www.ncbi.nlm.nih.gov/pubmed/33776407
http://dx.doi.org/10.1186/s41983-021-00287-3
work_keys_str_mv AT madohubert multiplesclerosispatientsandcovid19
AT adamczyksowamonika multiplesclerosispatientsandcovid19

Ejemplares similares